386 related articles for article (PubMed ID: 24685438)
1. Proteome changes in platelets after pathogen inactivation--an interlaboratory consensus.
Prudent M; D'Alessandro A; Cazenave JP; Devine DV; Gachet C; Greinacher A; Lion N; Schubert P; Steil L; Thiele T; Tissot JD; Völker U; Zolla L
Transfus Med Rev; 2014 Apr; 28(2):72-83. PubMed ID: 24685438
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update.
Seghatchian J; Tolksdorf F
Transfus Apher Sci; 2012 Apr; 46(2):221-9. PubMed ID: 22365926
[TBL] [Abstract][Full Text] [Related]
3. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage.
Schubert P; Culibrk B; Coupland D; Scammell K; Gyongyossy-Issa M; Devine DV
Transfusion; 2012 Feb; 52(2):397-408. PubMed ID: 21827504
[TBL] [Abstract][Full Text] [Related]
4. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light.
Mohr H; Steil L; Gravemann U; Thiele T; Hammer E; Greinacher A; Müller TH; Völker U
Transfusion; 2009 Dec; 49(12):2612-24. PubMed ID: 19682340
[TBL] [Abstract][Full Text] [Related]
5. Biomolecular Consequences of Platelet Pathogen Inactivation Methods.
Feys HB; Van Aelst B; Compernolle V
Transfus Med Rev; 2019 Jan; 33(1):29-34. PubMed ID: 30021699
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive proteomics study on platelet concentrates: Platelet proteome, storage time and Mirasol pathogen reduction technology.
Salunkhe V; De Cuyper IM; Papadopoulos P; van der Meer PF; Daal BB; Villa-Fajardo M; de Korte D; van den Berg TK; Gutiérrez L
Platelets; 2019; 30(3):368-379. PubMed ID: 29553857
[TBL] [Abstract][Full Text] [Related]
7. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
[TBL] [Abstract][Full Text] [Related]
8. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation.
Hechler B; Ohlmann P; Chafey P; Ravanat C; Eckly A; Maurer E; Mangin P; Isola H; Cazenave JP; Gachet C
Transfusion; 2013 Jun; 53(6):1187-200. PubMed ID: 23067365
[TBL] [Abstract][Full Text] [Related]
9. Mirasol PRT system inactivation efficacy evaluated in platelet concentrates by bacteria-contamination model.
Jocić M; Trkuljić M; Jovicić D; Borovcanin N; Todorović M; Balint B
Vojnosanit Pregl; 2011 Dec; 68(12):1041-6. PubMed ID: 22352265
[TBL] [Abstract][Full Text] [Related]
10. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
[TBL] [Abstract][Full Text] [Related]
11. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
[TBL] [Abstract][Full Text] [Related]
12. Towards the understanding of the UV light, riboflavin and additive solution contributions to the in vitro lesions observed in Mirasol®-treated platelets.
Abonnenc M; Crettaz D; Sonego G; Escolar G; Tissot JD; Prudent M
Transfus Clin Biol; 2019 Nov; 26(4):209-216. PubMed ID: 31563447
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of Intercept-treated platelets.
Prudent M; Crettaz D; Delobel J; Tissot JD; Lion N
J Proteomics; 2012 Dec; 76 Spec No.():316-28. PubMed ID: 22813878
[TBL] [Abstract][Full Text] [Related]
14. Proteomic analysis of platelets treated with gamma irradiation versus a commercial photochemical pathogen reduction technology.
Marrocco C; D'Alessandro A; Girelli G; Zolla L
Transfusion; 2013 Aug; 53(8):1808-20. PubMed ID: 23305084
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of yellow fever virus in plasma after treatment with methylene blue and visible light and in platelet concentrates following treatment with ultraviolet C light.
Faddy HM; Fryk JJ; Hall RA; Young PR; Reichenberg S; Tolksdorf F; Sumian C; Gravemann U; Seltsam A; Marks DC
Transfusion; 2019 Jul; 59(7):2223-2227. PubMed ID: 31050821
[TBL] [Abstract][Full Text] [Related]
16. Profiling of alterations in platelet proteins during storage of platelet concentrates.
Thiele T; Steil L; Gebhard S; Scharf C; Hammer E; Brigulla M; Lubenow N; Clemetson KJ; Völker U; Greinacher A
Transfusion; 2007 Jul; 47(7):1221-33. PubMed ID: 17581157
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis E virus is effectively inactivated in platelet concentrates by ultraviolet C light.
Praditya D; Friesland M; Gravemann U; Handke W; Todt D; Behrendt P; Müller TH; Steinmann E; Seltsam A
Vox Sang; 2020 Oct; 115(7):555-561. PubMed ID: 32383163
[TBL] [Abstract][Full Text] [Related]
18. In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates.
Abonnenc M; Sonego G; Crettaz D; Aliotta A; Prudent M; Tissot JD; Lion N
Transfusion; 2015 Sep; 55(9):2219-30. PubMed ID: 25873361
[TBL] [Abstract][Full Text] [Related]
19. Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma.
Kwon SY; Kim IS; Bae JE; Kang JW; Cho YJ; Cho NS; Lee SW
Vox Sang; 2014 Oct; 107(3):254-60. PubMed ID: 24806328
[TBL] [Abstract][Full Text] [Related]
20. Two pathogen reduction technologies--methylene blue plus light and shortwave ultraviolet light--effectively inactivate hepatitis C virus in blood products.
Steinmann E; Gravemann U; Friesland M; Doerrbecker J; Müller TH; Pietschmann T; Seltsam A
Transfusion; 2013 May; 53(5):1010-8. PubMed ID: 22905868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
